Brief: Cormedix Announces FDA Acceptance For Priority Review Of Supplemental NDA For Rezzayo
Mon 13:28
BRIEF-Cormedix Announces FDA Acceptance For Priority Review Of Supplemental NDA For Rezzayo Oct 19 (Reuters) - CorMedix Inc. CRMD.O:
ANNOUNCES FDA ACCEPTANCE FOR PRIORITY REVIEW OF SUPPLEMENTAL NDA FOR REZZAYO® (REZAFUNGIN) FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASES
FDA GRANTS PRIORITY REVIEW FOR REZZAYO WITH PDUFA TARGET ACTION DATE IN Q1 2027
TARGETS PROMOTIONAL LAUNCH FOR REZZAYO IN H2 2027 IF APPROVED
Source text: ID:nGNXVNfKz
Further company coverage: CRMD.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on CorMedix
See all newsBrief: Cormedix Announces FDA Acceptance For Priority Review Of Supplemental NDA For Rezzayo
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports
CorMedix Inc. reports results for the quarter ended June 30 - Earnings Summary